ABBV AbbVie Inc

Price (delayed)

$146.28

Market cap

$258.69B

P/E Ratio

19.43

Dividend/share

$5.71

EPS

$7.53

Enterprise value

$316.47B

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate ...

Highlights
The EPS has soared by 81% YoY and by 6% from the previous quarter
The company's net income has surged by 78% YoY and by 6% QoQ
The quick ratio has grown by 13% from the previous quarter but it has contracted by 8% YoY

Key stats

What are the main financial stats of ABBV
Market
Shares outstanding
1.77B
Market cap
$258.69B
Enterprise value
$316.47B
Valuations
Price to earnings (P/E)
19.43
Price to book (P/B)
16.17
Price to sales (P/S)
4.48
EV/EBIT
18.71
EV/EBITDA
12.56
EV/Sales
5.47
Earnings
Revenue
$57.82B
EBIT
$16.91B
EBITDA
$25.2B
Free cash flow
$21.92B
Per share
EPS
$7.53
Free cash flow per share
$12.38
Book value per share
$9.05
Revenue per share
$32.65
TBVPS
$23.08
Balance sheet
Total assets
$141.33B
Total liabilities
$125.3B
Debt
$69.61B
Equity
$15.99B
Working capital
-$2.35B
Liquidity
Debt to equity
4.35
Current ratio
0.93
Quick ratio
0.69
Net debt/EBITDA
2.29
Margins
EBITDA margin
43.6%
Gross margin
69.6%
Net margin
23.2%
Operating margin
30.6%
Efficiency
Return on assets
9.3%
Return on equity
86%
Return on invested capital
24.4%
Return on capital employed
15.6%
Return on sales
29.2%
Dividend
Dividend yield
3.9%
DPS
$5.71
Payout ratio
75.8%

ABBV stock price

How has the AbbVie stock price performed over time
Intraday
-0.76%
1 week
-2.21%
1 month
-10.25%
1 year
7.58%
YTD
-9.49%
QTD
-9.49%

Financial performance

How have AbbVie's revenue and profit performed over time
Revenue
$57.82B
Gross profit
$40.26B
Operating income
$17.69B
Net income
$13.41B
Gross margin
69.6%
Net margin
23.2%
The company's net income has surged by 78% YoY and by 6% QoQ
The net margin has surged by 69% year-on-year and by 5% since the previous quarter
ABBV's gross profit is up by 8% year-on-year
The operating income has grown by 7% YoY

Growth

What is AbbVie's growth rate over time

Valuation

What is AbbVie stock price valuation
P/E
19.43
P/B
16.17
P/S
4.48
EV/EBIT
18.71
EV/EBITDA
12.56
EV/Sales
5.47
The EPS has soared by 81% YoY and by 6% from the previous quarter
ABBV's P/E is 20% below its 5-year quarterly average of 24.2 and 7% below its last 4 quarters average of 20.9
AbbVie's equity has increased by 18% YoY and by 9% from the previous quarter
ABBV's price to book (P/B) is 2.6% lower than its last 4 quarters average of 16.6
ABBV's P/S is 9% above its 5-year quarterly average of 4.1
ABBV's revenue is up by 4.8% year-on-year

Efficiency

How efficient is AbbVie business performance
AbbVie's ROIC has soared by 105% YoY and by 8% from the previous quarter
AbbVie's return on assets has surged by 86% YoY and by 7% QoQ
The ROS has soared by 67% YoY and by 2.8% from the previous quarter
The ROE has soared by 51% YoY

Dividends

What is ABBV's dividend history
DPS
$5.71
Dividend yield
3.9%
Payout ratio
75.8%
Recent dividends

Financial health

How did AbbVie financials performed over time
AbbVie's total assets is 13% higher than its total liabilities
The quick ratio has grown by 13% from the previous quarter but it has contracted by 8% YoY
ABBV's current ratio is up by 11% since the previous quarter but it is down by 8% year-on-year
The company's debt to equity fell by 27% YoY and by 13% QoQ
AbbVie's equity has increased by 18% YoY and by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.